Literature DB >> 16006029

Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients.

Carlos A de Mendonça Lima1, Pierre Baumann, Marlyse Brawand-Amey, Christian Brogli, Sylvie Jacquet, Nathalie Cochard, Kerry Powell-Golay, Chin B Eap.   

Abstract

The effect of aging on steady-state plasma concentrations of citalopram (CIT) and desmethylcitalopram (DCIT) was investigated in 128 depressive patients treated with 10-80 mg/day CIT. They were separated into three groups, with age up to 64 years (mean age+/-S.D.: 47+/-12 years; n=48), between 65 and 79 years (72+/-1 years; n=57), and from 80 years or older (84+/-1 years; n=23). Body mass index (BMI), renal and hepatic functions were similar in the three groups. A large interindividual variability of plasma levels of CIT (16-fold) and DCIT (12-fold) was measured for a given dose. The mean plasma levels of CIT corrected for a 20 mg daily dose were 55% higher in the very elderly (>=80 years) patients (65+/-30 ng/ml; p<0.001) and 38% higher in the elderly (65-79 years) patients (58+/-24 ng/ml; p<0.001) when compared to the adult patients (42+/-17 ng/ml). DCIT mean plasma level was 38% higher (p<0.05) in the group of very elderly patients (22+/-10 ng/ml) when compared to the adult patients (16+/-9 ng/ml). As a consequence, the mean plasma concentration of CIT+DCIT was 48% higher in the very elderly patients (86+/-36 ng/ml; p<0.001) and 33% higher in the elderly patients (77+/-28 ng/ml; p<0.001) when compared to the adult patients (58+/-21 ng/ml). Age correlated significantly with CIT (r=0.43, p<0.001), DCIT (r=0.28, p<0.01), and CIT+DCIT plasma levels (r=0.44, p<0.001), and thus accounts for 18% of the variability of CIT plasma levels, with no influence of gender. The recommended dose reduction of CIT in elderly patients seems therefore justified.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16006029     DOI: 10.1016/j.pnpbp.2005.06.001

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  6 in total

1.  Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment.

Authors:  Perrine Courlet; Monia Guidi; Anaïs Glatard; Susana Alves Saldanha; Matthias Cavassini; Thierry Buclin; Catia Marzolini; Chin B Eap; Laurent A Decosterd; Chantal Csajka
Journal:  Br J Clin Pharmacol       Date:  2019-07-07       Impact factor: 4.335

Review 2.  FDA drug safety communications: a narrative review and clinical considerations for older adults.

Authors:  Zachary A Marcum; Joseph P Vande Griend; Sunny A Linnebur
Journal:  Am J Geriatr Pharmacother       Date:  2012-06-08

3.  Citalopram reduces endotoxin-induced fatigue.

Authors:  Jonas Hannestad; Nicole DellaGioia; Nyrma Ortiz; Brian Pittman; Zubin Bhagwagar
Journal:  Brain Behav Immun       Date:  2010-10-16       Impact factor: 7.217

4.  Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism.

Authors:  Bryan H King; Eric Hollander; Linmarie Sikich; James T McCracken; Lawrence Scahill; Joel D Bregman; Craig L Donnelly; Evdokia Anagnostou; Kimberly Dukes; Lisa Sullivan; Deborah Hirtz; Ann Wagner; Louise Ritz
Journal:  Arch Gen Psychiatry       Date:  2009-06

5.  Colorimetric method for the estimation of escitalopram oxalate in tablet dosage form.

Authors:  T Vetrichelvan; K Arul; M Sumithra; B Umadevi
Journal:  Indian J Pharm Sci       Date:  2010-03       Impact factor: 0.975

6.  A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation.

Authors:  Ayman Akil; Robert R Bies; Bruce G Pollock; Dimitrios Avramopoulos; D P Devanand; Jacobo E Mintzer; Anton P Porsteinsson; Lon S Schneider; Daniel Weintraub; Jerome Yesavage; David M Shade; Constantine G Lyketsos
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-11-26       Impact factor: 2.745

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.